Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2+
SponsorNational Cancer Institute (NCI)

About this trial

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant disorder will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation. Genetic linkage studies may be performed in situations in which the genetic basis of the disorder has not been elucidated.

...

Eligibility criteria

Qualifiers

One or more histologically proven or suspected renal carcinomas and/or cysts

Cerebellar, spinal, medullary or cerebral hemangioblastomas

Retinal angioma

Pancreatic neuro-endocrine carcinoma,micro cystadenoma and/or cysts

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

5,000 Participants
are grouped into 3 trial groups